May 17, 2020

BP Healthcare to invest Rs 100 mln to set up dental care network

Leading healthcare player
largest dental care network
firs
Admin
2 min
BP Healthcare to invest Rs 100 mln to set up dental care network
Leading healthcare player, BP Healthcare Group will be investing Rs 100 million over the next three years to establish the largest dental care network...

Leading healthcare player, BP Healthcare Group will be investing Rs 100 million over the next three years to establish the largest dental care network, the news reports said.

BP Healthcare will be adding up to 50 outlets by the end of the period which will complement the group’s overall thrust on wellness and health, the company said in a press statement. It also said, “The first dental clinic will open in the second week of September as the BP Specialist Centre in Glenmarie, Shah Alam to be followed by another three more at its specialist centres in Cheras, Klang and Ipoh in November.”  

BP Healthcare Deputy Chairman, Chevy Beh said, “Within the next three years, we will have 50 dental care clinics throughout the country. Each will cost RM2 million and the bulk of the investment will be spent on buying the best and latest equipments from abroad.”

The new company BP Dental Sdn Bhd has been established under the group to lead this new business as it moves up the value chain.

It aims to enhance its range and delivery of healthcare services to the customers. BP Healthcare was expected to add another 15 to 20 clinics next year and the remaining in 2014.

These clinics would be located within the existing BP outlets and dental checks will be included in BP Healthcare’s popular comprehensive Head2Toe health screening programme. Mr. Beh also said, “The establishment of BP Dental would bring about a new challenge for BP Healthcare to create greater awareness among Malaysians on the importance of oral health and adopt a preventive mindset.”

BP Healthcare Group is a diversified healthcare provider and Southeast Asia’s largest medical diagnostic chain with more than 90 outlets in Malaysia and a joint venture in Indonesia with well-known Ciputra Group.
 

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article